Therefore, therapies involving the activation of dopamine D2 receptors and inhibition of A2AR through therapies, such as IST, contribute to improving symptoms of movement dysfunction in PD patients [41,47]. The gene discussed is ADORA2A; the disease is Parkinson disease.